growth - Investors attracted to 20%+ revenue growth from Tyvaso franchise expansion, 50% operating margins…
Moderate sensitivity through valuation multiple compression rather than operational impact.
Watch on earnings: Tyvaso DPI weekly prescription volumes from Symphony Health data - leading indicator of ILD penetration, PAH patient prevalence estimates from registry data (REVEAL, COMPERA) - indicates total addressable market expansion, Remodulin generic filing activity at FDA and patent litigation calendar through 2028.
One Sentence Summary:
United Therapeutics: the story is balanced — tyvaso dpi adoption rates and ild market penetration - drives 60%+ of revenue growth expectations.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.